XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when combined with bortezomib or carfilzomib, could overcome acquired resistance in MM. PI-resistant myeloma cell lines both in...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Joel G., Kashyap, Trinayan, Dawson, Jana L., Gomez, Juan, Bauer, Alexis A., Grant, Steven, Dai, Yun, Shain, Kenneth H., Meads, Mark, Landesman, Yosef, Sullivan, Daniel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340237/
https://www.ncbi.nlm.nih.gov/pubmed/27806331
http://dx.doi.org/10.18632/oncotarget.12969

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340237/
https://www.ncbi.nlm.nih.gov/pubmed/27806331
http://dx.doi.org/10.18632/oncotarget.12969

Ejemplares similares